[The evaluation of the teratogenesis and embryotoxicity of the pharmaceutical product Boicil tablets. II. The effect of the pharmaceutical product Boicil tablets on early embryogenesis, organogenesis and the fetus in 3 successive generations of rats and mice].
The effect of Boicil tablets on early embryogenesis (the first 3 gestational days), organogenesis (the 10th, 11th and 12th gestational days) and fetus (the 18th and 19th gestational days) by its intraamniotic administration was followed up in three successive generations of mice and rats. Two doses were used (2 mg/kg body weight and 20 mg/kg body weight), estimated in relation with the maximum therapeutic daily dose in man, being administered in a single dose, per os. No inborn malformations or somatic abnormalities were recorded both in mothers and in their descendents for three successive generations. It is concluded that Boicil tablets is not teratogenic.